Brigatinib pharmacokinetic data from 442 adults (105 healthy volunteers and 337 patients with cancer) enrolled across five studies were adequately described by a three-compartment model with transit compartment input.

Albumin was included as a covariate on apparent clearance in the final population pharmacokinetic model, explaining approximately 5% of variability in apparent clearance.

Sex, age (18–83 years), race, body weight (40.6–172.0 kg), mild or moderate renal impairment (estimated glomerular filtration rate ≥ 32.7 mL/min/1.73 m2), total bilirubin (1–74 μmol/L), aspartate aminotransferase (10–99 U/L), and alanine aminotransferase (5–129 U/L) were not found to impact brigatinib exposure.